Drug Profile
Filgrastim biosimilar - Lupin
Alternative Names: Filgrastim - Lupin; LupifilLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Lupin
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 19 May 2016 Launched for Neutropenia (Adjunctive treatment, In adults) in India before May 2016 (SC) (Lupin website, July 2016)
- 23 Apr 2014 Phase-III clinical trials for Neutropenia (adjunct to chemotherapy in patients with non-myeloid malignancies) in India (SC)
- 05 Mar 2013 Registered for Neutropenia (adjunct to chemotherapy in patients with non-myeloid malignancies) in India (SC)